Literature DB >> 23891063

Ischemia-modified albumin in pregnancy.

Alberto Rossi1, Nadia Bortolotti, Sara Vescovo, Irene Romanello, Leonardo Forzano, Ambrogio Pietro Londero, Guido Ambrosini, Diego Marchesoni, Francesco Curcio.   

Abstract

OBJECTIVE: In normal pregnancies, a hypoxic intrauterine environment seems necessary for early trophoblast development. In this context, maternal serum levels of ischemia-modified albumin (IMA) are elevated, reflecting the oxidative stress associated with placental development. The aim of this study was to evaluate IMA and pregnancy-associated plasma protein A (PAPP-A) in mothers bearing small-for-gestational-age (SGA) fetuses compared to normal pregnancies. STUDY
DESIGN: A prospective study was performed between June 2010 and June 2011. Serum total albumin, IMA and PAPP-A concentrations were determined in 81 pregnant women in three different periods: 1st trimester, 2nd trimester and postpartum. Two groups of subjects were retrospectively identified: Group (1) mothers bearing appropriate-for-gestational-age (AGA) fetuses, and Group (2) mothers bearing SGA fetuses. Serum total albumin and IMA concentrations were determined in 198 non-pregnant women as controls.
RESULTS: Serum IMA concentrations increase during gestation. IMA/albumin serum levels in the 1st trimester were significantly higher in subjects of Group (2) (p<0.05), whereas values of serum PAPP-A MoM were significantly lower (p<0.05).
CONCLUSIONS: Elevated IMA serum levels together with low levels of PAPP-A were detected in the 1st trimester in mothers bearing SGA fetuses, and this may reflect early placental changes occurring before clinical manifestation of SGA.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Fetal growth restriction; Ischemia-modified albumin; Oxidative stress; Trophoblast development

Mesh:

Substances:

Year:  2013        PMID: 23891063     DOI: 10.1016/j.ejogrb.2013.06.037

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  7 in total

1.  Placental aging and oxidation damage in a tissue micro-array model: an immunohistochemistry study.

Authors:  Ambrogio P Londero; Maria Orsaria; Stefania Marzinotto; Tiziana Grassi; Arrigo Fruscalzo; Angelo Calcagno; Serena Bertozzi; Nastassia Nardini; Enrica Stella; Ralph J Lellé; Lorenza Driul; Gianluca Tell; Laura Mariuzzi
Journal:  Histochem Cell Biol       Date:  2016-04-22       Impact factor: 4.304

2.  Ischemia Modified Albumin as a Marker of Oxidative Stress in Normal Pregnancy.

Authors:  Jyotirmayee Bahinipati; Prakash Chandra Mohapatra
Journal:  J Clin Diagn Res       Date:  2016-09-01

3.  Association of Maternal Serum Ischemia Modified Albumin (IMA) with Placental Histopathological Changes and Fetomaternal Outcome: A Prospective Case Control Study in Normotensive and Pre-eclamptic Women.

Authors:  Shyam Pyari Jaiswar; Shikha Verma; Monica Agrawal; Sujata Deo; Madhumati Goel; Abbas Ali Mahdi
Journal:  J Obstet Gynaecol India       Date:  2022-02-12

Review 4.  A Systematic Review and Meta-Analysis of Serum Concentrations of Ischaemia-Modified Albumin in Acute Ischaemic Stroke, Intracerebral Haemorrhage, and Subarachnoid Haemorrhage.

Authors:  Arduino A Mangoni; Angelo Zinellu
Journal:  Biomolecules       Date:  2022-04-29

Review 5.  Serum Concentrations of Ischaemia-Modified Albumin in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Arduino A Mangoni; Angelo Zinellu
Journal:  J Clin Med       Date:  2022-07-20       Impact factor: 4.964

Review 6.  Ischemia-modified albumin: Crosstalk between fatty acid and cobalt binding.

Authors:  James P C Coverdale; Kondwani G H Katundu; Amélie I S Sobczak; Swati Arya; Claudia A Blindauer; Alan J Stewart
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2018-07-20       Impact factor: 4.006

Review 7.  Ischemia-Modified Albumin: Origins and Clinical Implications.

Authors:  Alla Shevtsova; Iuliia Gordiienko; Viktoriia Tkachenko; Galyna Ushakova
Journal:  Dis Markers       Date:  2021-07-19       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.